| 2017-05-18 08:52:10 | Globus Medical robot delay a 'minor setback,' says LeerinkLeerink analyst Richard Newitter calls the FDA delaying approval of Globus Medical's ExcelsiusGPS robotic guidance system a "minor setback." The analyst views the issue as timing more than anything else and continues to have confidence in the company's organic revenue growth acceleration prospects. He recommends buying Globus shares on weakness and reiterates an Outperform rating on the name. | |
|---|---|---|
| ||
| ||
| | |
| , … |
| |
| ||
| |
| | |
| | |
| | |
| ||
| |
| , |
| |
|---|---|---|
| , |
| |
| ||
| | |
| , … |
|
| , |
| |
|---|---|---|
| | |
| , … |
| |
| | |
| |
| ||
| | |
| | |
| , |
| |
|